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Many pathogens take advantage of the dependence of the host on the interaction of 
hundreds of extracellular proteins with the glycosaminoglycans heparan sulfate to 
regulate homeostasis and use heparan sulfate as a means to adhere and gain access 
to cells. Moreover, mucosal epithelia such as that of the respiratory tract are protected 
by a layer of mucin polysaccharides, which are usually sulfated. Consequently, the 
polydisperse, natural products of heparan sulfate and the allied polysaccharide, 
heparin have been found to be involved and prevent infection by a range of viruses 
including S-associated coronavirus strain HSR1. Here we use surface plasmon 
resonance and circular dichroism to measure the interaction between the SARS-CoV-
2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin. The 
data demonstrate an interaction between the recombinant surface receptor binding 
domain and the polysaccharide. This has implications for the rapid development of a 
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Introduction 
 
Heparin, the second most widely used drug by weight globally, is formulated as a 
polydisperse, heterogenous natural product. Unfractionated heparin, low molecular 
weight heparins and heparinoids are clinically approved as anticoagulants / thrombotic 
with excellent safety, stability, bioavailability and pharmacokinetic profiles. Crucially, 
heparin and its derivatives, some of which lacking significant anticoagulant activity 1, 
are an under-exploited antiviral drug class, despite possessing broad-spectrum 
activity against a multitude of distinct viruses, including coronaviridae and SARS-
associated coronavirus strain HSR1 2, in addition to flaviviruses 3,4, herpes 5, influenza 
6 and HIV 7,8. 
 
Traditional drug development processes are slow and ineffective against emerging 
public health threats such as the current SARS-CoV-2 coronavirus outbreak which 
makes the repurposing of existing drugs a timely and attractive alternative. Heparin, a 
well-tolerated anticoagulant pharmaceutical, has been used safely in medicine for over 
80 years and alongside its anticoagulant activities, its ability to prevent viral infection, 
including coronaviridae, has been described1. Furthermore, the closely related 
glycosaminoglycan (GAG) member, heparan sulfate (HS), is known to bind CoV 
surface proteins and to be used by coronavirus for its attachment to target cells9. 
 
Currently, there are no commercially available medicinal products designed to treat 
and/or prevent infections associated with the new SARS-CoV-2 coronavirus outbreak. 
Here, we describe preliminary tests for the ability of the SARS-CoV-2 S1 RBD to bind 
heparin, an important prerequisite for the underpinning research related to the 




Methods & Materials 
 
2.1 Recombinant expression of SARS-CoV-2 S1 RBD 
 
Residues 330−583 of the SARS-CoV-2 Spike Protein (GenBank: MN908947) were 
cloned upstream of a N-terminal 6XHisTag in the pRSETA expression vector and 
transformed into SHuffle® T7 Express Competent E. coli (NEB, UK). Protein 
expression was carried out in MagicMedia™ E. coli Expression Media (Invitrogen, UK) 
at 30°C for 24 hrs, 250 rpm. The bacterial pellet was suspended in 5 mL lysis buffer 
(BugBuster Protein Extraction Reagent, Merck Millipore, UK; containing DNAse) and 
incubated at room temperature for 30 mins. Protein was purified from inclusion bodies 
using IMAC chromatography under denaturing conditions. On-column protein 
refolding was performed by applying a gradient with decreasing concentrations of the 
denaturing agent (6-0 M Urea). After extensive washing, protein was eluted using 20 
mM NaH2PO4, pH 8.0, 300 mM NaCl, 500 mM imidazole. Fractions were pooled and 
buffer-exchanged to phosphate-buffered saline (PBS; 140 mM NaCl, 5 mM NaH2PO4, 
5 mM Na2HPO4, pH 7.4; Lonza, UK) using a PD-10 desalting column (GE Healthcare, 
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2.2 Secondary structure determination of SARS-CoV-2 S1 RBD by circular 
dichroism spectroscopy 
 
The circular dichroism (CD) spectra of the SARS-CoV-2 S1 RBD in PBS was recorded 
using a J-1500 Jasco CD spectrometer, Spectral Manager II software and a 0.2 mm 
pathlength quartz cuvette (Hellma, USA) scanning at 100 nm.min-1 with a 1 nm 
resolution throughout the range of λ = 190 - 260 nm. All spectra obtained were the 
mean of five independent scans post calibration with camphorsulfonic acid. SARS-
CoV-2 S1 RBD was buffer-exchanged (prior to spectral analysis) using a 5 kDa 
Vivaspin centrifugal filter (Sartorius, Germany) at 12,000 g, thrice. Collected data was 
analysed with Spectral Manager II software prior to processing with GraphPad Prism 
7, using a second order polynomial smoothing through 21 neighbours. Secondary 
structural prediction was calculated through the BeStSel analysis server 10.To ensure 
the CD spectral change of SARS-CoV-2 S1 RBD in the presence of heparin was not 
altered owing to the addition of the heparin alone, which is known to possess CD 
spectra at high concentrations 11,12 a differential spectrum was analysed. The 
theoretical, summative CD spectra was confirmed to differ from the observed 
experimental CD spectra, thereby indicating that the change in the CD spectra 
compared to that of SARS-CoV-2 S1 RBD alone is a result of a conformational change 
upon binding to porcine mucosal heparin (Leo Pharma, UK).  
 
 
2.3 Surface Plasmon Resonance determination of SARS-CoV-2 S1 RBD binding 
to unfractionated heparin. 
 
Human FGF2 was produced as described by Duchesne et al. 13. Porcine mucosal 
heparin was biotinylated at the reducing end using hydroxylamine biotin 
(ThermoFisher, UK) as described by Thakar et al. 14. Heparin (20 µL 50 mg/mL) was 
reacted with 20 µL hydroxylamine-biotin in 40 µL 300 mM aniline (Sigma-Aldrich, UK) 
and 40 µL 200 mM acetate pH 6 for 48 h at 37 °C. Free biotin was removed by gel-
filtration chromatography on Sephadex G25 (GE LifeSciences, UK). 
 
A P4SPR, multi-channel Surface Plasmon Resonance (SPR) instrument (Affinté 
Instruments; Montréal, Canada) was utilised with a gold sensor chip that was plasma 
cleaned prior to derivatization. A self-assembled monolayer of mPEG thiol and biotin 
mPEG was formed by incubating the chip in a 1 mM solution of these reagents at a 
99:1 molar ratio in ethanol for 24 hrs 15. The chip was rinsed with ethanol and placed 
into the instrument. PBS (1X) was used as the running buffer for the three sensing and 
a fourth background channel at 500 µl.min-1, using an Ismatec pump. Twenty 
micrograms of streptavidin (Sigma, UK; 1mL in PBS) were injected over the four 
sensor channels. Subsequently, biotin-heparin (1 mL) was injected over the three 
sensing channels. 
 
In binding experiments, the ligate was injected over the three sensing channels, diluted 
to the concentration indicated in the figure legends at 500 µl.min-1. Sensor surfaces 
with bound FGF2 were regenerated by a wash with 2 M NaCl, whereas 20 mM HCl 
was used to regenerate surfaces with bound SARS-CoV-2 S1 RBD as 2 M NaCl was 
ineffective to disrupt binding. Background binding to the underlying streptavidin bound 
to the mPEG/biotin mPEG self-assembled monolayer was determined by injection 
over the control channel. Responses are reported as the change in plasmon 
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3.1 Surface Plasmon Resonance binding studies. 
 
FGF2, a well characterised heparin-binding protein was used to test the successful 
functionalization of the three sensing channels with biotin-heparin. Injection of 1 mL 
100 nM FGF2 over the sensing channels elicited a significant response (Fig. 1A, 
injection between the red arrows). However, 100 nM FGF2 elicited no response in the 
control channel, functionalized solely with streptavidin (not shown). The bound FGF2 
was removed by a wash with 2 M NaCl, as done previously for the IASys optical 
biosensor 16. 
 
When 65 nM SARS-CoV-2 S1 RBD was injected over the three sensing channels, 
there was an initial decrease in signal, followed by an increase, indicative of binding 
(Fig. 1B between red arrows). The initial decrease was due to a slightly lower refractive 
index of the SARS-CoV-2 S1 RBD protein solution compared to the PBS of the running 
buffer, which caused a negative bulk shift. This is demonstrated by the injection of 65 
nM solution over the control channel, functionalized with just streptavidin, where there 
was a decrease in response, followed by a return to baseline when the channel was 
returned to running buffer (Fig. 1C, between red arrows).  These data demonstrate 
that the SARS-CoV-2 S1 RBD protein binds specifically to heparin immobilised 




3.2 Secondary structure determination of SARS-CoV-2 S1 RBD protein by 
circular dichroism spectroscopy 
 
Circular dichroism (CD) spectroscopy detects changes in protein secondary structure 
that occur in solution using UV radiation. Upon binding, conformational changes are 
detected and quantified using spectral deconvolution 17. Indeed, SARS-CoV-2 S1 RBD 
underwent conformational change in the presence of heparin (Figure 2). Combined, 
Helix content increased by 4.8% and global beta-sheet content decreased by 4.4%. 
The observed changes further demonstrate that the SARS-CoV-2 S1 RBD interacts 
with heparin in aqueous solution of physiological significance, whereby the major 
changes induced by heparin are those associated with antiparallel and helix content. 
 
Basic amino acids are known to dictate the binding between proteins and heparin. 
With that in mind, primary sequence analysis of the expressed protein domain and 
analysis of the modelled SARS-CoV-2 S1 RBD structure (Figure 3) shows that there 
are several potential heparin binding sites and, more importantly, that theses patches 
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Figure 1. Interaction of FGF2 and Spike RBD with immobilised heparin. Reducing-end 
biotinylated heparin was immobilised on a streptavidin functionalized P4SPR sensor 
surface. PBS running buffer flow rate was 500 µL.min-1. The data for the three sensing 
channels are reported as an average response. Protein injections are delimited by the red 
arrows. A Injection of 100 nM FGF2. B 64 nM S1 RBD protein. C 64 nM S1 RBD protein 
over a streptavidin surface (no heparin functionalization). 
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Figure 2. The structural change of the SARS-CoV-2 S1 RBD observed in the presence 
of heparin by circular dichroism (CD) spectroscopy. (A) CD spectra of 200 μg/mL spike 
1 alone (purple) or with 30 μg heparin (orange) in phosphate buffered saline pH 7.4. 
Theoretical sum of spike 1 alone and 30 μg of heparin (control) if no interaction was 
observed (black). (B) Δ secondary structure (%) of (A). A 2.4% increase in helix and 2.2% 
decrease in antiparallel secondary structural features were calculated (BestSel) for the 
observed spectrum compared to that of the theoretical, summative spectrum of the SARS-




Figure 3. SARS-CoV-2 S1 RBD protein model. Basic amino acids that are solvent 
accessible on the surface are indicated (dark blue); these can be observed to form a 
continuous patch. 
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Discussion and Conclusion 
 
The rapid spread of SARS-CoV-2 represents a significant challenge to global health 
authorities and, as there are no currently approved drugs to treat, prevent and/or 
mitigate its effects, repurposing existing drugs is both a timely and appealing strategy. 
Heparin, a well tolerated anticoagulant drug, has been used successfully for over 80 
years with limited and manageable side effects. Furthermore, heparin belongs to a 
unique class of pharmaceuticals that has effective antidotes available, which makes 
its use safer. 
 
Studying SARS-CoV-2 Spike protein structure and behaviour in solution is a vital step 
for the development of effective therapeutics against SARS-CoV-2. Here, the ability of 
the SARS-CoV-2 S1 RBD to bind pharmaceutical heparin has been studied using 
spectroscopic techniques in concert with molecular modelling. The data show that 
SARS-CoV-2 S1 RBD binds to heparin and that upon binding, a significant structural 
change is induced. Moreover, moieties of basic amino acid residues, known to 
constitute heparin binding domains, are solvent accessible on the SARS-CoV-2 S1 
RBD surface and form a continuous patch that is suitable for heparin binding. 
 
Glycosaminoglycans are ubiquitously present on almost all mammalian cells and this 
class of carbohydrates are central to the strategy employed by coronaviridae to attach 
to host cells. Heparin has previously been shown to inhibit SARS-associated 
coronavirus strain HSR1 cell invasion 2,18 and this, in concert with the data presented 
within this study, supports the utilisation of glycosaminoglycan-derived 
pharmaceuticals against SARS-associated coronavirus. Furthermore, this study 
strongly supports the repurposing of heparin and its derivatives as antiviral agents, 
providing a rapid countermeasure against the current SARS-CoV-2 outbreak. 
 
It is noteworthy that even pharmaceutical-grade heparin preparations remain a 
polydisperse mixture of natural products, containing both anticoagulant and non-
anticoagulant saccharide structures. The latter may prove to be an invaluable resource 
for next-generation, biologically active, antiviral agents that display negligible 
anticoagulant potential, whilst the former remains tractable to facile, chemical (and 
enzymatic) engineering strategies to ablate their anticoagulation activities. 
 
The subfractionation of existing heparin preparations against anticoagulant activities 
(with proven low-toxicity profiles, good bioavailability and industrial-scale 
manufacturing) for off-label pathologies, provides an attractive strategy for quickly and 
effectively responding to COVID-19 and for the development of next generation 
heparin-based therapeutics. 
 
Such drugs will be amenable to routine parenteral administration through currently 
established routes and additionally, direct to the respiratory tract via nasal 
administration, using nebulised heparin, which would be unlikely to gain significant 
access to the circulation. Thus, the anticoagulant activity of heparin, which can in any 
event be engineered out, would not pose a problem. Importantly, such a route of 
administration would not only be suitable for prophylaxis, but also for patients under 
mechanical ventilation 19. 
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